Review: Neoadjuvant Dual ICIs Offer Better Response Than Anti-PD1 Monotherapy in High-Risk Resectable Melanoma
AJMC,
A pooled analysis of clinical trials conducted over a 5-year period shows that combining nivolumab (Opdivo) and ipilimumab (Yervo…
A pooled analysis of clinical trials conducted over a 5-year period shows that combining nivolumab (Opdivo) and ipilimumab (Yervo…
_.